With the practice-changing introduction of CDKi in the treatment of BC, the therapeutic landscape has changed tremendously and is shifting even more to neoadjuvant, adjuvant, HER2-targeted, and even maintaining regimen. Here, ERBB2 is linked to breast cancer.